| Michael E Karnasiewicz, MD | |
|
500 Chase Pkwy, Suite 2a, Waterbury, CT 06708-3346 | |
| (203) 755-6677 | |
| (203) 573-9182 |
| Full Name | Michael E Karnasiewicz |
|---|---|
| Gender | Male |
| Speciality | Neurological Surgery |
| Location | 500 Chase Pkwy, Waterbury, Connecticut |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861459182 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 017466 (Connecticut) | Primary |
| Entity Name | Neurosurgery Orthopaedics & Spine Specialists Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831359215 PECOS PAC ID: 8820087463 Enrollment ID: O20040510000696 |
News Archive
Consumers know they will have to pay out of their pockets if they use medical providers outside their insurers' networks. But because of a little-noticed change, they may find themselves with even bigger bills than they expect.
New preliminary data from a pilot study in the Netherlands indicates that imaging tools may help address the most challenging clinical dilemma of prostate cancer care as identified by the hearing of the House Oversight and Government Reform Committee and its expert witnesses last week: to treat or not treat, AdMeTech Foundation's President and CEO Dr. Faina Shtern said today.
The Associated Press: An effort to streamline the entangled field of Medicare drug plans could mean as many as 3 million seniors "could force 3 million seniors to switch plans next year whether they like it or not, says an independent analysis," by Avalere Health: "beneficiaries will see their prescription plan eliminated as part of a new effort by Medicare to winnow down duplicative coverage and offer consumers more meaningful choices. Seniors would not lose coverage, but they could see changes in their premiums and copayments."
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael E Karnasiewicz, MD 500 Chase Pkwy, Suite 2a, Waterbury, CT 06708-3346 Ph: (203) 755-6677 | Michael E Karnasiewicz, MD 500 Chase Pkwy, Suite 2a, Waterbury, CT 06708-3346 Ph: (203) 755-6677 |
News Archive
Consumers know they will have to pay out of their pockets if they use medical providers outside their insurers' networks. But because of a little-noticed change, they may find themselves with even bigger bills than they expect.
New preliminary data from a pilot study in the Netherlands indicates that imaging tools may help address the most challenging clinical dilemma of prostate cancer care as identified by the hearing of the House Oversight and Government Reform Committee and its expert witnesses last week: to treat or not treat, AdMeTech Foundation's President and CEO Dr. Faina Shtern said today.
The Associated Press: An effort to streamline the entangled field of Medicare drug plans could mean as many as 3 million seniors "could force 3 million seniors to switch plans next year whether they like it or not, says an independent analysis," by Avalere Health: "beneficiaries will see their prescription plan eliminated as part of a new effort by Medicare to winnow down duplicative coverage and offer consumers more meaningful choices. Seniors would not lose coverage, but they could see changes in their premiums and copayments."
Novartis announced today that it has entered into a clinical development agreement with Pfizer which will include a study combining tropifexor and one or more Pfizer compounds for the treatment of NASH, including an Acetyl CoA-Carboxylase (ACC) Inhibitor (PF-05221304, a Diacylglycerol O-Acyltransferase 2 (DGAT2) Inhibitor (PF-06865571, and a Ketohexokinase (KHK) Inhibitor (PF-06835919).
› Verified 5 days ago
Alan S. Waitze, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 500 Chase Pkwy, Suite 2a, Waterbury, CT 06708 Phone: 203-755-6677 Fax: 203-573-1982 | |
Dr. Jarob N Mushaweh, M.D. Neurological Surgery Medicare: Medicare Enrolled Practice Location: 500 Chase Pkwy, Suite 2a, Waterbury, CT 06708 Phone: 203-755-6677 Fax: 203-755-7166 | |
Dr. David Forshaw, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 500 Chase Pkwy, Waterbury, CT 06708 Phone: 203-755-6677 | |
Stephen A. Torrey, M.D. Neurological Surgery Medicare: Not Enrolled in Medicare Practice Location: 500 Chase Pkwy, Suite 2a, Waterbury, CT 06708 Phone: 203-755-6677 Fax: 203-755-7166 |